JPWO2019246299A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019246299A5 JPWO2019246299A5 JP2020570747A JP2020570747A JPWO2019246299A5 JP WO2019246299 A5 JPWO2019246299 A5 JP WO2019246299A5 JP 2020570747 A JP2020570747 A JP 2020570747A JP 2020570747 A JP2020570747 A JP 2020570747A JP WO2019246299 A5 JPWO2019246299 A5 JP WO2019246299A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- amino acid
- composition
- acid entity
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 143
- 229940024606 amino acid Drugs 0.000 claims description 91
- 235000001014 amino acid Nutrition 0.000 claims description 82
- -1 leucine amino acid Chemical class 0.000 claims description 74
- 108010016626 Dipeptides Proteins 0.000 claims description 46
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 39
- 229960004308 acetylcysteine Drugs 0.000 claims description 39
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 39
- 229960003136 leucine Drugs 0.000 claims description 36
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 30
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 28
- 206010022489 Insulin Resistance Diseases 0.000 claims description 27
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- 239000004475 Arginine Substances 0.000 claims description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
- 235000009697 arginine Nutrition 0.000 claims description 18
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- 229930182816 L-glutamine Natural products 0.000 claims description 16
- 239000004395 L-leucine Substances 0.000 claims description 16
- 235000019454 L-leucine Nutrition 0.000 claims description 16
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 14
- 229960003624 creatine Drugs 0.000 claims description 14
- 239000006046 creatine Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 12
- 208000019423 liver disease Diseases 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 229960004295 valine Drugs 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 208000016361 genetic disease Diseases 0.000 claims description 6
- 229960002885 histidine Drugs 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 235000004252 protein component Nutrition 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000017701 Endocrine disease Diseases 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102100038246 Retinol-binding protein 4 Human genes 0.000 claims description 4
- 101710137011 Retinol-binding protein 4 Proteins 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 208000030172 endocrine system disease Diseases 0.000 claims description 4
- 208000007345 glycogen storage disease Diseases 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 235000021119 whey protein Nutrition 0.000 claims description 4
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims description 3
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims description 2
- 206010000599 Acromegaly Diseases 0.000 claims description 2
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 201000005948 Donohue syndrome Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 2
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 208000007932 Progeria Diseases 0.000 claims description 2
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 102000007156 Resistin Human genes 0.000 claims description 2
- 108010047909 Resistin Proteins 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 208000026928 Turner syndrome Diseases 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000021588 free fatty acids Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000003914 insulin secretion Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000037356 lipid metabolism Effects 0.000 claims description 2
- 208000006132 lipodystrophy Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000007625 mitochondrial abnormality Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687727P | 2018-06-20 | 2018-06-20 | |
| US62/687,727 | 2018-06-20 | ||
| US201962794134P | 2019-01-18 | 2019-01-18 | |
| US62/794,134 | 2019-01-18 | ||
| PCT/US2019/038037 WO2019246299A1 (en) | 2018-06-20 | 2019-06-19 | Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527671A JP2021527671A (ja) | 2021-10-14 |
| JP2021527671A5 JP2021527671A5 (https=) | 2022-09-08 |
| JPWO2019246299A5 true JPWO2019246299A5 (https=) | 2022-09-08 |
Family
ID=67185732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570747A Pending JP2021527671A (ja) | 2018-06-20 | 2019-06-19 | インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210275479A1 (https=) |
| EP (1) | EP3810122A1 (https=) |
| JP (1) | JP2021527671A (https=) |
| CN (1) | CN112689508A (https=) |
| MA (1) | MA52953A (https=) |
| WO (1) | WO2019246299A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CN112823018A (zh) | 2018-06-20 | 2021-05-18 | 胺细拉健康公司 | 制备氨基酸组合物的方法 |
| CN111514276B (zh) * | 2020-06-29 | 2021-07-27 | 黑龙江中医药大学 | 短肽Asp-His-Tyr在制备治疗多囊卵巢综合征的药物中的应用 |
| WO2022266480A1 (en) * | 2021-06-17 | 2022-12-22 | Axcella Health Inc. | Methods of predicting liver fat content and uses thereof |
| WO2023009444A1 (en) | 2021-07-26 | 2023-02-02 | Axcella Health Inc. | Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19 |
| EP4643658A1 (en) * | 2024-04-29 | 2025-11-05 | Laboratorios Ern S.A. | Dietary product for hypoproteic diet |
| CN119679774A (zh) * | 2024-11-15 | 2025-03-25 | 北京体育大学 | 预防或治疗代谢性疾病的药物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022927A3 (cs) * | 2000-02-01 | 2003-06-18 | Muscletech Research And Development Inc. | Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly |
| US20050176827A1 (en) * | 2002-05-10 | 2005-08-11 | Lee Steve S. | Compositions and methods for glycogen synthesis |
| CN1557301A (zh) * | 2004-01-15 | 2004-12-29 | 高春平 | 降低老年肥胖型糖尿病人血糖和血脂的组合物 |
| US20050233014A1 (en) * | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for affecting homeostasis and metabolism in a mammalian body |
-
2019
- 2019-06-19 CN CN201980054586.0A patent/CN112689508A/zh active Pending
- 2019-06-19 JP JP2020570747A patent/JP2021527671A/ja active Pending
- 2019-06-19 US US17/254,027 patent/US20210275479A1/en not_active Abandoned
- 2019-06-19 MA MA052953A patent/MA52953A/fr unknown
- 2019-06-19 WO PCT/US2019/038037 patent/WO2019246299A1/en not_active Ceased
- 2019-06-19 EP EP19736883.0A patent/EP3810122A1/en not_active Withdrawn
-
2023
- 2023-07-27 US US18/360,381 patent/US20240238232A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527671A5 (https=) | ||
| JP2020530845A5 (https=) | ||
| JP2020504108A5 (https=) | ||
| Kanai et al. | Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity | |
| JP2020502183A5 (https=) | ||
| JP2021529736A5 (https=) | ||
| Christensen | Role of amino acid transport and countertransport in nutrition and metabolism. | |
| JPWO2019246299A5 (https=) | ||
| TW201919601A (zh) | 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法 | |
| US20240238232A1 (en) | Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions | |
| CA2631647A1 (en) | Use of branched-chain amino acids for the treatment of muscle loss | |
| WO2020001203A1 (zh) | 一种复方氨基酸维生素注射液及其应用 | |
| JPWO2019036471A5 (https=) | ||
| JP2021527670A5 (https=) | ||
| JP2009538832A5 (https=) | ||
| JP2010506887A (ja) | 栄養不足状態の治療のためのシトルリンの使用 | |
| EP1945199A1 (en) | Leucine rich composition | |
| JP2004521123A5 (https=) | ||
| Abachi et al. | Beneficial effects of fish and fish peptides on main metabolic syndrome associated risk factors: Diabetes, obesity and lipemia | |
| RU2009126763A (ru) | Лечение общих расстройств развития | |
| JP2011523626A5 (https=) | ||
| JP2010513259A5 (https=) | ||
| JP2534139B2 (ja) | 腎不全用経口アミノ酸製剤 | |
| Fijlstra et al. | Continuous Enteral Administration Can Enable Normal Amino Acid Absorption in Rats with Methotrexate-Induced Gastrointestinal Mucositis2 | |
| US20120252723A1 (en) | Regulating the Amino Acid Pool Used for the Acute-Phase Protein Synthesis |